Hierarchical involvement of Bak, VDAC1 and Bax in cisplatin-induced cell death

Area of Science:

• Cell Biology
• Cancer Research
• Molecular Biology

Background:

• Cisplatin (CDDP) is a chemotherapy drug used for non-small cell lung cancer.
• The precise mechanisms of CDDP-induced apoptosis, particularly mitochondrial outer membrane permeabilization (MMP), are not fully understood.
• Targeting apoptotic pathways is a key strategy in cancer therapy.

Purpose of the Study:

• To investigate the role of voltage-dependent anion channel 1 (VDAC1) in cisplatin-induced apoptosis in non-small cell lung cancer (NSCLC).
• To elucidate the specific molecular pathway involving VDAC1, Bak, and Bax during CDDP treatment.
• To explore VDAC1 as a potential therapeutic target for overcoming cisplatin resistance.

Main Methods:

• Screening of small-interfering RNAs (siRNAs) to identify genes involved in CDDP-induced apoptosis.
• Assessment of VDAC1 knockdown and chemical inhibition effects on apoptosis markers.
• Analysis of mitochondrial transmembrane potential, plasma membrane permeabilization, and protein conformational changes (Bax, Bak).
• Utilizing specific inhibitors like ABT-737 to modulate apoptotic pathways.

Main Results:

• VDAC1 knockdown significantly reduced CDDP-induced cell death and apoptosis markers in NSCLC cells.
• VDAC1 inhibition decreased mitochondrial potential dissipation and plasma membrane permeabilization.
• VDAC1 acts upstream of Bax activation but downstream of Bak activation in the MMP pathway.
• Reversal of Bax activation failure in VDAC1-depleted cells using ABT-737 restored CDDP cytotoxicity.

Conclusions:

• A novel hierarchical pathway for CDDP-induced MMP involving Bak, VDAC1, and Bax has been identified.
• VDAC1 plays a critical, facultative role in regulating MMP during cytotoxic stress.
• Targeting VDAC1 presents a promising strategy to enhance the efficacy of cisplatin chemotherapy in NSCLC.